Introduction
Cell death by apoptosis plays a pivotal role in the regulation of various physiological or pathological conditions and has also been implied to mediate therapy-induced cytotoxicity, e.g. in response to cytotoxic drug treatment, g-irradiation or cytotoxic cytokines Schulze-Ostho et al., 1998; Kaufmann and Earnshaw, 2000; Debatin, 1997; Fulda et al., 1997 Fulda et al., , 1998b . Apoptosis pathways may be initiated through dierent entry sites, such as death receptors (receptor pathway) or mitochondria (mitochondrial pathway) resulting in activation of eector caspases . Stimulation of death receptors of the tumor necrosis factor (TNF) receptor superfamily such as CD95 (APO-1/Fas) results in receptor aggregation and recruitment of the adaptor molecule Fas-associated death domain (FADD) and caspase-8 . Upon recruitment caspase-8 becomes activated and initiates apoptosis by direct cleavage of downstream eector caspases . A second pathway is initiated at the mitochondrial level (Kroemer and Reed, 2000) . Apoptogenic factors such as cytochrome c, apoptosis inducing factor (AIF), caspase-2 or caspase-9 are released from mitochondria into the cytosol triggering caspase-3 activation through formation of the cytochrome c/Apaf-1/caspase-9-containing apoptosome complex (Kroemer and Reed, 2000; Susin et al., 1999; Hengartner, 2000) . In these cells, caspase-8 is activated downstream of mitochondria promoting further cleavage of eector caspases. Signals originating from the CD95 receptor may be linked to mitochondria by Bid, a BH3 domain containing protein of the Bcl-2 family which assumes cytochrome-c-releasing activity upon cleavage by caspase-8 thereby initiating a mitochondrial ampli®cation loop (Kroemer and Reed, 2000) .
In CD95-mediated apoptosis we recently identi®ed two dierent apoptosis signaling cell types (Scadi et al., 1998) . In type I cells, caspase-8 is activated at the CD95 DISC in large quantities resulting in direct processing of caspase-3. This step is independent of mitochondrial activation and cannot be blocked by overexpression of Bcl-2. In contrast, in type II cells, the amount of active caspase-8 generated at the DISC is limited. In type II cells, apoptosis proceeds through mitochondrial perturbations and generation of active caspase-3 and -8 downstream of mitochondria and Bcl-2 overexpression blocked activation of both caspase-3 and -8.
Besides CD95 ligand and TNFa, TRAIL is another member of the TNF/NGF superfamily of death inducing ligands . TRAIL can interact with ®ve distinct receptors, two of which contain a cytoplasmic death domain and signal apoptosis. Analysis of the native TRAIL death-inducing signaling complex (DISC) revealed ligand-dependent Figure 1 Eect of Bcl-2 overexpression on TRAIL-induced apoptosis. (a) Eect of Bcl-2 overexpression on TRAIL-induced DNA fragmentation in neuroblastoma cells. SHEP neuroblastoma cells transfected with vector control (Neo) or Bcl-2 were treated for indicated times with 3 ± 100 ng/ml TRAIL and/or 1 mg/ml CHX. Apoptosis was determined by FACS analysis of propidium iodide stained DNA content. Percentage of speci®c apoptosis was calculated as follows: 1006[experimental apoptosis (%) 7 spontaneous apoptosis (%) / 100% 7 spontaneous apoptosis (%)]. Mean and s.d. of triplicates are shown, similar results were obtained in three independent experiments. (b) Eect of Bcl-2 overexpression on TRAIL-induced phosphatidylserine exposure in neuroblastoma cells. SHEP neuroblastoma cells transfected with vector control (Neo) or Bcl-2 were treated for 24 h with 100 ng/ml TRAIL and 1 mg/ml CHX. Apoptosis was determined by FACS analysis of FITC-annexin V stained cells. Fluorescence intensity (abscissa) is plotted against cell counts (ordinate). (c) Eect of Bcl-2 overexpression on TRAIL-induced long term survival in neuroblastoma cells. SHEP neuroblastoma cells transfected with vector control (Neo) or Bcl-2 were left untreated or were treated for 7 days with 100 ng/ml TRAIL. Clonogenic survival was determined by staining colonies with crystal violet and visualized by digital camera. (d) Eect of Bcl-2 overexpression on TRAIL-induced DNA fragmentation in SKW lymphoblastoid cells. SKW cells transfected with vector control (Neo) or Bcl-2 were treated for indicated times with 3 ± 100 ng/ml TRAIL and/or 1 mg/ml CHX. Apoptosis was determined by FACS analysis of propidium iodide stained DNA content as described above. (e) TRAIL DISC analysis in SHEP and SKW cells. SHEP or SKW cells were left untreated or were treated with 1000 ng/ml TRAIL before lysis. TRAIL was added to lysates of untreated cells for precipitation of unstimulated TRAIL receptors. DISC formation was analysed by immunoprecipitation and Western blot analysis as described in Materials and methods
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S Fulda et al recruitment of FADD and caspase-8 demonstrating that TRAIL utilizes a pathway similar to the one used by the CD95 receptor (Sprick et al., 2000) . TRAIL has been shown to induce apoptosis in various tumor cell lines in vitro and also suppresses the growth of TRAIL sensitive tumors in SCID mice in vivo Walczak et al., 1999) . Unlike the other death ligands CD95 or TNFa, systemic administration of soluble human TRAIL did not cause systemic toxicity in mice or nonhuman primates, although further studies may be necessary to evaluate the possible cytoxicity of TRAIL on human normal tisues, e.g. hepatocytes Walczak et al., 1999; Lawrence et al., 2001; Ichikawa et al., 2001; Nagane et al., 2001) . Thus, TRAIL may be a promising novel therapeutic agent for human cancer.
Resistance of many tumors such as neuroblastoma to current treatment protocols still remains a major concern in cancer therapy (Berthold et al., 1990) . Deregulated apoptosis programs may contribute to tumor progression and treatment resistance (Debatin, 1997; Kaufmann and Earnshaw, 2000) . Thus, the identi®cation of molecular defect(s) in apoptosis signaling is crucial to develop novel strategies to target resistance. Defects in apoptosis pathways may occur at dierent levels, e.g. at the mitochondrial level by Bcl-2 or during the eector phase by inhibitor of apoptosis proteins (IAP's) (Kroemer, 1997; Deveraux and Reed, 1999) . Bcl-2 is highly expressed in many cell lines and primary tumors including neuroblastoma or malignant brain tumors, and its expression has been associated with drug resistance (Kroemer, 1997; Hoehner et al., 1995; Fels et al., 2000) . Thus, novel strategies are necessary to target resistance of tumors with Bcl-2 overexpression. We previously found that overexpression of Bcl-2 protected SHEP neuroblastoma cells against apoptosis induced by agonistic anti-CD95 monoclonal antibody or cytotoxic drugs (Fulda et al., 1998a (Fulda et al., , 2000 . Recent data suggest that TRAIL induced apoptosis independent of mitochondria and could be used in Bcl-2 overexpressing tumor cells which were resistant to chemotherapy Keogh et al., 2000; Kim et al., 2001; Gazitt et al., 1999; Suliman et al., 2001) . In search for strategies to overcome resistance, we therefore investigated the role of Bcl-2 in TRAIL-induced apoptosis in the present study.
Results

Bcl-2 overexpression inhibits TRAIL-induced apoptosis in neuroblastoma cells
We previously found that overexpression of Bcl-2 protected SHEP neuroblastoma cells against apoptosis induced by agonistic anti-CD95 monoclonal antibody or cytotoxic drugs. To determine the role of Bcl-2 in TRAIL-induced apoptosis, we compared the pattern of apoptosis following treatment with TRAIL in SHEP neuroblastoma cells transfected with Bcl-2 expression vector or control vector. Overexpression of Bcl-2 almost completely inhibited apoptosis in response to treatment with TRAIL ( Figure 1a ). Combined treatment with TRAIL together with the protein synthesis inhibitor CHX further sensitized vector control cells for apoptosis induction, whereas Bcl-2 overexpression protected SHEP cells even against treatment with TRAIL together with CHX ( Figure 1a) . Apoptosis was also determined by annexin V staining. Following treatment with TRAIL and CHX the majority of vector control cells were positive for annexin V, whereas only a small percentage of Bcl-2 transfected cells were positive for annexin V (Figure 1b) . To test whether Bcl-2 overexpression only causes a delay in the apoptosis response or has an eect on long-term survival, we performed clonogenic assays. Treatment of vector control cells with TRAIL almost completely abrogated colony formation compared to untreated vector control cells, whereas the eect of TRAIL treatment on colony formation was blocked by Bcl-2 overexpression ( Figure  1c ). This demonstrates that Bcl-2 overexpression not only delayed cell death, but also had a protective eect on long term survival of tumor cells in response to TRAIL treatment. We also investigated the eect of Bcl-2 overexpression on TRAIL-induced apoptosis in SKW lymphoblastoid cells, since TRAIL has previously been reported to signal apoptosis independent of mitochondria. In SKW cells, Bcl-2 overexpression did not prevent apoptosis following treatment with TRAIL or the combination of TRAIL and CHX ( Figure 1d ). In addition, DISC formation following treatment with TRAIL was reduced in SHEP cells compared to SKW cells ( Figure 1e ). These ®ndings suggest that Bcl-2 overexpression conferred protection against TRAILinduced apoptosis in a cell type speci®c manner.
Bcl-2 overexpression inhibits TRAIL-induced mitochondrial alterations
To exclude that the dierential protection of Bcl-2 in SHEP and SKW cells against TRAIL-induced apoptosis was the result of dierent expression levels of Bcl-2, we analysed Bcl-2 protein expression. High Bcl-2 expression was detected in the cytosolic and mitochondrial fraction of both SHEP and SKW cells (Figure 2a ). This indicates that the dierent protective eect of Bcl-2 against TRAIL-induced apoptosis could not be attributed to low Bcl-2 protein levels in SKW cells. In addition, overexpression of Bcl-2 similarly blocked loss of the mitochondrial membrane potential following treatment with TRAIL and/or CHX in both SHEP and SKW cells ( Figure 2b) . Also, the release of cytochrome c, AIF and Smac from mitochondria was inhibited in SHEP and SKW cells (Figure 2c ). These ®ndings indicate that overexpression of Bcl-2 similarly blocked mitochondrial perturbations upon treatment with TRAIL in both SHEP and SKW cells.
To see whether caspases were activated upstream of mitochondria we analysed the eect of caspase inhibitors on the mitochondrial membrane potential in response to treatment with TRAIL. Loss of the mitochondrial membrane potential upon TRAIL treatment was markedly inhibited in the presence of the broad range caspase inhibitor zVAD.fmk or the relatively speci®c caspase-8 inhibitor zIETD.fmk in both SHEP and SKW cells (Figure 2d ). This indicates that caspases such as caspase-8 were activated prior to mitochondrial dysfunction at the receptor level following ligation of TRAIL receptors.
Bcl-2 overexpression reduces TRAIL-induced activation of caspases in neuroblastoma cells
To gain insight into the dierential regulation of TRAIL-induced apoptosis, we then analysed activation of caspases by Western blot. In SHEP cells, overexpression of Bcl-2 reduced cleavage of the initiator caspase-8, Bid and caspase-9, and inhibited cleavage of caspase-3 and caspase-7 into active fragments ( Figure  3a) . Interestingly, in SHEP vector control cells cleavage of caspase-3 resulted in generation of the p24 intermediate fragment and the p17/10 active subunits, whereas in Bcl-2 overexpressing SHEP cells, only the p24 intermediate fragment, but no active p17/10 subunits were detected (Figure 3a ). This suggests that Bcl-2 did not prevent the initial cleavage of caspase-3 between the large and small subunit to generate the p24 intermediate fragment, but blocked further autoprocessing of caspase-3 into the p17/10 active subunits. In contrast, in SKW cells Bcl-2 overexpression did not inhibit cleavage of caspase-8, caspase-7, caspase-3 and cleavage of Bid, while cleavage of caspase-9 was reduced in Bcl-2 overexpressing SKW cells (Figure 3b ). Also, we tested for activation of eector caspases by analysing cleavage of cellular substrates such as DFF45, a prototype substrate of caspase-3, and PARP, a prototype substrate of caspase-7 (Germain et al., 1999; Wolf et al., 1999; Slee et al., 2001) . Importantly, cleavage of DFF45 and PARP was completely blocked by Bcl-2 in SHEP cells compared to vector control cells (Figure 3c ). Also by¯ow cytometry, Bcl-2 overexpression was found to inhibit activation of caspase-3 in SHEP cells (data not shown). In contrast, in SKW cells Bcl-2 overexpression did not inhibit cleavage of DFF45 or PARP (Figure 3d ). Together, these ®ndings indicate that in SKW cells, TRAIL-induced activation of caspase-8 upstream of mitochondria directly translated into activation of executioner caspases such as caspase-3 and cleavage of cellular substrates independent of mitochondria. In contrast, in SHEP neuroblastoma cells, the generation of active caspase-3 and -7 fragments and cleavage of caspase substrates was completely blocked by Bcl-2 indicating that a mitochondrial ampli®cation step was required for complete activation of eector caspases and apoptosis.
Bcl-2 overexpression inhibits TRAIL-induced cleavage of XIAP in neuroblastoma cells and XIAP overexpression confers protection against TRAIL IAP's such as XIAP exert their antiapoptotic function, at least in part, downstream of the mitochondrial checkpoint by inhibiting proteolytically processed caspases including caspase-3, caspase-7 and caspase-9. In addition, XIAP has recently been reported to act as a ubiquitin-ligase for activated caspase-3 or -7 thereby promoting the degradation of activated caspases. Therefore, we analysed XIAP expression by Western blot analysis. Upon TRAIL treatment XIAP was cleaved in SHEP vector control cells, whereas cleavage of XIAP was completely inhibited in Bcl-2 transfected SHEP cells (Figure 4a) . The slight reduction of fulllength XIAP expression without appearance of cleavage products observed in Bcl-2 transfected SHEP cells (Figure 4a ) may be due to inhibition of protein synthesis by CHX consistent with previous results (Fulda et al., 2000) . In contrast, XIAP was similarly cleaved in vector control or Bcl-2 transfected SKW cells (Figure 4a ). To further investigate whether apoptosis was blocked at a level downstream of mitochondria by absent cleavage of XIAP in SHEP cells, we analysed the eect of XIAP overexpression. As shown in Figure 4b stable transfected clones expressed high levels of XIAP protein.
Apoptosis in response to treatment with TRAIL or TRAIL together with CHX was strongly inhibited by XIAP (Figure 4c ) demonstrating that TRAIL-induced apoptosis was also regulated by inhibitor of apoptosis proteins such as XIAP in SHEP cells.
Bcl-2 overexpression inhibits TRAIL-induced apoptosis in glioblastoma and breast carcinoma cells
To exclude that our ®ndings were restricted to SHEP neuroblastoma cells, we then investigated TRAILinduced apoptosis in LN-229 glioblastoma and MCF-7 breast carcinoma cells. High expression levels of Bcl-2 in transfected cells was controlled by Western blot analysis (Figure 5a ). While treatment with TRAIL alone was only marginally eective to induce apoptosis, treatment with TRAIL together with CHX induced apoptosis in LN-229 or MCF-7 cells in a dose and time-dependent manner (Figure 5b, c) . In contrast, overexpression of Bcl-2 protected LN-229 or MCF-7 cells against apoptosis triggered by TRAIL or the combination of TRAIL and CHX (Figure 5b, c) . Western blot analysis revealed that Bcl-2 delayed cleavage of caspase-8 and Bid and strongly inhibited cleavage of caspase-9, caspase-7 or caspase-3 ( Figure  5d , e). Importantly, Bcl-2 completely blocked cleavage of XIAP and PARP (Figure 5d , e). These ®ndings indicate that a mitochondrial ampli®cation step was also required in LN-229 glioblastoma and MCF-7 breast carcinoma cells for full activation of caspases, cleavage of antiapoptotic proteins such as XIAP and apoptosis in response to treatment with TRAIL.
Discussion
Despite aggressive therapies, resistance to current treatment protocols has been a major obstacle in clinical oncology. Most anticancer agents act through induction of apoptosis in target cells and defects in apoptosis programs may confer resistance (Debatin, Kaufmann and Earnshaw, 2000) . Apoptosis is mediated through both the death receptor and the mitochondrial pathway (Hengartner, 2000) . At least in some cellular systems, mitochondria also seem to be necessary for death receptor-induced apoptosis (Kroemer and Reed, 2000) . The mitochondrial pathway of apoptosis can be blocked by the antiapoptotic protein Bcl-2 which has been localized to cellular membranes, e.g. the mitochondrial membrane (Kroemer, 1997) . Bcl-2 is highly expressed in many cell lines and primary tumors including neuroblastoma or glioblastoma (Kroemer, 1997; Hoehner et al., 1995; Fels et al., 2000) . High Bcl-2 expression has been correlated with poor prognosis in some instances and also likely plays a role in chemoresistance (Kroemer, 1997; Hoehner et al., 1995; Fels et al., 2000) . Thus, novel strategies are necessary to target resistance, e. ). We previously found that Bcl-2 overexpression blocked apoptosis induced by CD95 ligation or cytotoxic drugs in neuroblastoma cells (Fulda et al., 1998a (Fulda et al., , 2000 . In search for strategies to overcome resistance, we therefore investigated the role of Bcl-2 in TRAIL-induced apoptosis in the present study.
Here we report that overexpression of Bcl-2 conferred protection against TRAIL-induced apoptosis in neuroblastoma, glioblastoma or breast carcinoma cell lines. Ampli®cation of the TRAIL-induced death signal by mitochondria was required for full activation of the caspase cascade to inactivate XIAP in these cells. This conclusion is based on several pieces of evidence.
Bcl-2 inhibited cleavage of the eector caspases caspase-3 or caspase-7 into active subunits and cleavage of cellular caspase substrates, e.g. cleavage of DFF45, a prototype substrate of caspase-3, and cleavage of PARP, a primary target of caspase-7 (Germain et al., 1999; Wolf et al., 1999; Slee et al., 2001 ). Cleavage of caspase-8 and Bid was partially blocked by Bcl-2 suggesting that caspase-8 was activated upstream and downstream of mitochondria. These results support recent data demonstrating that executioner caspases, e.g. caspase-3, can serve as a feedback loop by cleaving caspase-8 to amplify the apoptotic process (Slee et al., 1999 (Slee et al., , 2001 ). In addition, our ®ndings indicate that executioner caspases can serve as a feedforward loop by cleaving XIAP to allow the caspase cascade to progress to completion, since full activation of the caspase cascade through a mitochondrial ampli®cation step was necessary for cleavage and inactivation of XIAP. Also, overexpression of XIAP conferred protection against TRAIL. Since XIAP binds to and inhibits processed caspase-9, -7 and -3 and can also promote caspase degradation through its ubiquitin-protein ligase activity, downregulation of XIAP will amplify the apoptotic process (Holcik et al., 2001; Suzuki et al., 2001) . This points to an additional control level of the TRAIL signaling pathway downstream of mitochondria by XIAP that is linked to the mitochondrial checkpoint, since Bcl-2 can regulate inactivation of XIAP by caspase cleavage and by Smac release from mitochondria (Holcik et al., 2001; Du et al., 2000) . XIAP is inactivated by at least two mechanisms, e.g. by proteolytic cleavage and by XIAP-interacting proteins such as Smac (Holcik et al., 2001) . Of the known human IAP related proteins, XIAP is the most potent inhibitor and a direct role of XIAP in the resistance of cancer cells to radiation and chemotherapy was recently demonstrated using a XIAP antisense approach (Holcik et al., 2001; Sasaki et al., 2000) . Thus, the TRAIL signaling pathway may be regulated in a cell type dependent manner at dierent levels, e.g. at the mitochondrial level by Bcl-2 and at a level downstream of mitochondria by XIAP.
Initial studies on the biochemical pathways of TRAIL-induced apoptosis in lymphoid cell lines demonstrated that overexpression of Bcl-2 did not confer protection, whereas apoptosis following anticancer drug treatment was blocked Keogh et al., 2000; Kim et al., 2001; Gazitt et al., 1999; Suliman et al., 2001) . These data suggested that TRAIL induced apoptosis via a caspase cascade independent of mitochondria and could be used in Bcl-2 overexpressing tumor cells which were resistant to chemotherapy. In contrast, recent reports and our ®ndings indicate that Bcl-2 also conferred protection against TRAIL in some tumors (Hinz et al., 2000; Sun et al., 2001; Rokhlin et al., 2001) . The dierences between the studies may be due to dierent recombinant TRAIL preparations which may vary in their cytotoxic potential (Lawrence et al., 2001; Ichikawa et al., 2001) . Dierent expression levels of Bcl-2 may also play a role. However, we found no association between Bcl-2 protein expression levels and protection against TRAIL in the present study, since SKW lymphoblastoid cells were not protected by Bcl-2 against TRAIL despite high levels of Bcl-2 protein. Alternatively, there may be intrinsic dierences between cell types, since a lack of protection by Bcl-2 against TRAIL has predominantly been reported for lymphoid cell lines Keogh et al., 2000; Kim et al., 2001; Gazitt et al., 1999; Suliman et al., 2001) . To this end, we found protection by Bcl-2 against TRAIL treatment in solid tumor cell lines derived from neuroblastoma, glioblastoma or breast carcinoma cell lines, whereas Bcl-2 did not confer protection in the lymphoblastoid cell line SKW indicating for the ®rst time a cell type dependent (type I and type II) regulation of the TRAIL signaling pathway.
For CD95, we previously identi®ed two dierent apoptosis signaling cell types (Scadi et al., 1998) . In type I cells, e.g. SKW lymphoblastoid cells, activation of caspase-8 following CD95 crosslinking directly proceeded to activation of executioner caspases such as caspase-3 independent of mitochondria. In these cells, overexpression of Bcl-2 did not confer protection against CD95-induced apoptosis. In contrast, in type II cells apoptosis following CD95 crosslinking depended on mitochondrial activity which was blocked by Bcl-2 overexpression. SHEP neuroblastoma cells display characteristics of both type I and type II cells. In SHEP cells, loss of the mitochondrial membrane potential depended on caspase activity indicating that activation of caspases, e.g. caspase-8 following TRAIL receptor ligation occurred prior to loss of the mitochondrial membrane potential which is characteristic of type I cells. In addition, activation of caspases partially depended on mitochondria and was inhibited by Bcl-2 overexpression, since activation of caspase-8 did not directly translate into full activation of caspase-3, a feature characteristic of type II cells. Our data on Bcl-2 inhibition of TRAIL-induced apoptosis suggest a similar cell type dependent (type I and type II) organization of the TRAIL signaling pathway.
Bcl-2 is highly expressed in many cell lines and primary tumors including neuroblastoma or malignant brain tumors, and its expression has been associated with drug resistance (Kroemer, 1997; Hoehner et al., 1995; Fels et al., 2000) . Current attempts to improve cancer survival largely depend on strategies to target tumor cell resistance and on the development of novel treatment modalities, e.g. immunotherapy, gene therapy or cytotoxic cytokines such as TRAIL. TRAIL is a promising candidate for clinical investigation, since it induces apoptosis in a broad spectrum of human tumor cell lines and exhibits potent antitumor activity without normal tissue toxicity in various human cancer xenograft models (Nagane et al., 2001) . However, our ®ndings indicate that TRAIL may not be eective in some tumors, e.g. in tumors with enhanced Bcl-2 or XIAP expression. Thus, our ®ndings may have important implications for cancer therapy. Because the potential success of novel treatment approaches including TRAIL largely depend on intact apoptosis pathways in tumor cells, strategies that target the SHEP neuroblastoma or SKW lymphoblastoid cells transfected with vector control (Neo) or Bcl-2 were treated for 24 h with 100 ng/ml and 1 mg/ml CHX. Mitochondrial, cytosolic or nuclear extracts were prepared as described in Materials and methods. Expression of cytochrome c, AIF or Smac was determined by Western blot analysis as described above. (d) Eect of caspase inhibition on loss of DC m . Cells were treated for 12 h with 100 ng/ml TRAIL, 50 mM zVAD.fmk and/or 50 mM zIETD.fmk. DC m was determined as described above 
Materials and methods
Cell culture
SHEP neuroblastoma, LN-229 glioblastoma, MCF-7 breast carcinoma or SKW6.4 B lymphoblastoid transfected with vector control or Bcl-2 were maintained in RPMI 1640 medium (Life Technologies, Inc., Eggenstein, Germany) as previously described (Fulda et al., 1998a; Scadi et al., 1998; Rieger et al., 1998; Ruiz-Ruiz et al., 2000) . Cells (0.5610 5 ) per ml were cultured in 24-well-plates for determination of apoptosis or in 75 cm 2¯a sks (Falcon, Heidelberg, Germany) for protein isolation.
Determination of apoptosis
Cells were incubated with recombinant human TRAIL (PeproTech Inc., Rocky Hill, NJ, USA), cycloheximide (CHX, Sigma, Deisenhofen, Germany), benzyloxycarbonylVal-Ala-Asp-¯uoromethylketone (zVAD.fmk; Bachem, Heia b c 3 ng/ml; 10 ng/ml; 30 ng/ml; 100 ng/ml Figure 4 Inhibition of TRAIL-induced apoptosis by XIAP. (a) Eect of Bcl-2 overexpression on TRAIL-induced cleavage of XIAP. SHEP neuroblastoma (upper panel) or SKW lymphoblastoid (lower panel) cells transfected with vector control (Neo) or Bcl-2 were treated for indicated times with 3 ± 100 ng/ml and 1 mg/ml CHX. Protein expression was determined by Western blot analysis as described above. In addition to XIAP, a nonspeci®c XIAP immune-reactive molecule migrating slightly larger than XIAP was detected using the mouse monoclonal anti-XIAP antobody H62120 (Deveraux and Reed, 1999) . (b) Analysis of XIAP expression. SHEP neuroblastoma cells were transfected with vector control (Neo) or XIAP cDNA. Protein expression of myc-tagged XIAP was determined by Western blot analysis as described above. (c) Eect of XIAP overexpression on TRAIL-induced apoptosis. SHEP neuroblastoma cells transfected with vector control (Neo) or XIAP were treated for indicated times with 3 ± 100 ng/ml TRAIL and/ or 1 mg/ml CHX. Apoptosis was determined as described above a b c d e 3 ng/ml; 10 ng/ml; 30 ng/ml; 100 ng/ml 3 ng/ml; 10 ng/ml; 30 ng/ml; 100 ng/ml or Bcl-2 were treated for indicated times with 3 ± 100 ng/ml TRAIL and/or 1 ± 3 mg/ml CHX. Apoptosis was determined as described above. (d and e) Eect of Bcl-2 overexpression on TRAIL-induced activation of caspases. LN-229 glioblastoma (d) or MCF-7 breast carcinoma (e) cells transfected with vector control (Neo) or Bcl-2 were treated for indicated times with 100 ng/ml TRAIL and/or 1 ± 3 mg/ml CHX. Protein expression was determined by Western blot analysis as described above
Regulation of TRAIL-induced apoptosis S Fulda et al delberg, Germany) or benzyloxycarbonyl-Ile-Glu(OMe)-ThrAsp(OMe)-¯uoromethylketone (zIETD.fmk; Bachem). Quanti®cation of DNA fragmentation was performed by¯uores-cence-activated cell-sorting (FACS) analysis of propidium iodide stained nuclei as previously described (Fulda et al., 1998a; Nicoletti et al., 1991) . Analysis of phosphatidylserine exposure was performed by¯ow cytometry of FITC-annexin V stained cells (Bender Med System, Munich, Germany) according to the manufacturer's instructions.
Clonogenicity assay
Cells (10 3 ) were seeded in a six-well plate and treated for 7 days with 100 ng/ml TRAIL. Clonogenic survival was determined by staining colonies using crystal violet and visualized by digital camera.
Western blot and DISC analysis
Western blot analysis was performed as previously described (Fulda et al., 1997) using mouse anti-caspase-8 monoclonal antibody C15 (1 : 10 dilution of hybridoma supernatant) , mouse anti-caspase-3 monoclonal antibody (1 : 1000, Transduction Laboratories, Lexington, KY, USA), mouse anti-caspase-7 monoclonal antibody (1 : 1000, Transduction Laboratories), rabbit anti-caspase-9 polyclonal antibody (1 : 1000, PharMingen, San Diego, CA, USA), rabbit anti-poly(ADP-ribose) polymerase (PARP) polyclonal antibody (1 : 5000, Boehringer Mannheim, Mannheim, Germany), mouse anti-XIAP monoclonal antibody (1 : 1000, H62120, Transduction Laboratories), mouse anti-DFF45 monoclonal antibody (1 : 1000, Transduction Laboratories), mouse anti-Bcl-2 monoclonal antibody (1 : 1000, Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1 : 1000, PharMingen), rabbit anti-AIF polyclonal antibody (1 : 5000, kindly provided by G Kroemer), rabbit anti-Smac polyclonal antibody (1 : 5000, kindly provided by X Wang), mouse anti-COX4 monoclonal antibody (1 : 1000, Clontech Laboratories, Inc., Palo Alto, CA, USA), or mouse anti-b-actin monoclonal antibody (1 : 5000, Sigma) followed by goat anti-mouse IgG or goat anti-rabbit IgG (1 : 5000, Santa Cruz Biotechnology). Analysis of the TRAIL DISC was performed as previously described (Mitsiades et al., 2000) . Enhanced chemiluminescence (ECL, Amersham Pharmacia, Freiburg, Germany) was used for detection. Expression of b-actin was used to control for equal gel loading.
Transfection experiments
SHEP neuroblastoma cells were transfected with expression plasmid pcDNA3 vector containing myc-tagged XIAP cDNA or empty vector using lipofectamine transfection reagent (Life Technologies, Inc.) and cultured in 0.5 mg/ml G418 (Life Technologies, Inc.).
Preparation of mitochondria, cytosolic or nuclear extracts
Preparation of mitochondria or cytosolic extracts was performed using the ApoAlert cell fractionation kit (Clontech Laboratories) according to the manufacturer's instructions.
Assessment of mitochondrial transmembrane potential
The cationic lipophilic¯uorochrome 3,3'-dihexyloxacarbocyanide iodide (DiOC 6 (3)) (460 ng/ml, Molecular Probes, Eugene, OR, USA) was used to measure the mitochondrial transmembrane potential (DC m ). Cells were incubated for 15 min at 378C in the presence of the¯uorochrome, washed in PBS/1% FCS and immediately analysed by¯ow cytometry (FACScan, Becton Dickinson). DiOC 6 (3) was recorded in uorescence 1.
